MedTrace Logo

Oxytocin in Spectrum Autism Disorders

NCT03183674 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2019-10-28

No results posted yet for this study

Summary

Observe effects of oxytocin on individuals with autism spectrum disorder

Conditions

  • Autistic Disorder

Interventions

DRUG

Oxytocin

Single dose oxytocin 45 minutes before the test

OTHER

placebo

saline solution 0,9% spray nasal

Sponsors & Collaborators

  • University of Sao Paulo General Hospital

    lead OTHER

Principal Investigators

  • Debora Zambori · Instituto de Psiquiatria

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
3 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-15
Primary Completion
2017-07-20
Completion
2018-05-15

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03183674 on ClinicalTrials.gov